Programmed death 1 (PD-1) and ligand (PD-L1) inhibitors in head and neck squamous cell carcinoma: A meta-analysis

查看全文 作　　者：Dylan [1]A.Levy;Jaimin [1]J.Patel;Shaun [1]A.Nguyen;W.Nicholas [1]Jungbauer;David [1,2]M.Neskey;Ezra [3]E.W.Cohen;Chrystal [4,5]M.Paulos;John [6]A.Kaczmar;Hannah [4,5]M.Knochelmann;Terry [1]A.Day 机构地区：[1]Department of Otolaryngology-Head and Neck Surgery,Medical University of South Carolina,Charleston,South Carolina,USA;[2]Department of Cell and Molecular Pharmacology and Developmental Therapeutics,Medical University of South Carolina,Charleston,South Carolina,USA;[3]Department of Medicine,Division of Hematology-Oncology,University of California,San Diego,La Jolla,California,USA;[4]Department of Microbiology and Immunology,Medical University of South Carolina,Charleston,South Carolina,USA;[5]SDepartment of Dermatology and Dermatologic Surgery,Medical University of South Carolina,Charleston,South Carolina,USA;[6]Division of Hematology&Oncology,Medical University of South Carolina,Charleston,South Carolina,UsA 出　　处：《World Journal of Otorhinolaryngology-Head and Neck Surgery》索引2022年第8卷第3期,共10页 摘　　要：Background: PD-1 and PD-L1 inhibitors have emerged as promising treatments for patients with head and neck squamous cell carcinoma (HNSCC).Methods: Systematic review and meta-analysis of PD-1 and PD-L1 inhibitors in HNSCC. Outcomes: median overall survival (mOS), median progression-free survival (mPFS), Response Evaluation Criteria in Solid Tumors (RECIST) and treatment-related adverse events (TRAEs).Results: Eleven trials reported data on 1088 patients (mean age: 59.9 years, range: 18-90). The total mOS was 7.97 months (range: 6.0-16.5). Mean mPFS for all studies was 2.84 months (range: 1.9-6.5). PD-1 inhibitors had a lower rate of RECIST Progressive Disease than PD-L1 inhibitors (42.61%, 95% confidence interval [CI]: 36.29-49.06 vs. 56.79%, 95% CI: 49.18-64.19,P < 0.001). The rate of TRAEs of any grade (62.7%, 95% CI: 59.8-65.6) did not differ.Conclusions: Meta-analysis shows the efficacy of PD-1 and PD-L1 inhibitors in HNSCC and suggests a possible difference in certain RECIST criterion between PD-1 and PD-L1 inhibitors. Future work to investigate the clinical significance of these findings is warranted. 关 键 词：ANTIBODIES disease progression head and neck neoplasms HUMANIZED META-ANALYSIS MONOCLONAL squamous cell carcinoma of the neck